[Treatment of subacute and chronic forms of hepatitis as well as of chronic degenerative liver diseases using Silymarin].
D000208:Acute Disease; D000410:Alanine Transaminase / Q000378:metabolism; D000438:Alcohols / Q000627:therapeutic use; D000469:Alkaline Phosphatase / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000378:metabolism; D002908:Chronic Disease; D005069:Evaluation Studies as Topic; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D006505:Hepatitis / Q000188:drug therapy* / Q000201:enzymology; D006506:Hepatitis A / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D000438:Alcohols; D005419:Flavonoids; D007136:Immunoglobulins; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase
Zur Behandlung subakuter und chronsicher Formen der Hepatitis sowie chronische degenerativer Lebererkrankungen mit Silymarin.